SecBot SecBot

ACRV

Acrivon Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001781174 Biotech & Drug Discovery
$1.73 −0.03 (−1.70%)
Oct 23 4:00 PM ET · prev $1.76
Market cap
$75.4M
Micro cap
Median target
🔒 Subscribers only
1 year
−16.4%
from $2.07 · Oct 24
30 days
−18.4%
from $2.12
52-week range
$1.29–3.01
−43% from high · low Mar 30
Avg volume 20D
219.5K
shares / day
Short interest
1.62M
≈3.8% of shares · +34.4%
Days to cover
4.4
at average volume
Insider net
-$40.4K
0 buyers · 6 sellers · since Mar 1
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
56°
Neutral · 4 mentions this week
Filing reports
2
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 12, 2026
Strongest NEUTRAL Acrivon Therapeutics announced presentations at the AACR D3 conference highlighting preclinical and early…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $40.4K.

  • InstitutionsMIXED

    Q2 2026: 6 added (0 new), 5 trimmed or exited.

  • Short sellersBUILDING

    Short interest +34.4% to 1.62M shares. 4.4 days to cover, ≈3.8% of shares.

  • TrendDOWNTREND

    13% below its 50-day average.

  • SocialQUIET

    Crowd 56° (neutral) this week from 4 mentions: 1 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RA CAPITAL MANAGEMENT, L.P.ADD12,229,396$21.8M
VANGUARD CAPITAL MANAGEMENT LLCADD952,008$1.7M
VANGUARD FIDUCIARY TRUST COADD184,128$327.7K
JANE STREET GROUP, LLCTRIM74,648$132.9K
NORTHERN TRUST CORPADD67,202$119.6K
UBS Group AGADD43,850$78.1K
DIMENSIONAL FUND ADVISORS LPADD29,332$52.2K
Squarepoint Ops LLCTRIM13,309$23.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jan 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Jan 9, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Nov 25, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 14, 2025Oppenheimer
MAINTAIN
MAINTAINOutperform
May 16, 2025Jones Trading
DOWNGRADE
DOWNGRADEHold
May 15, 2025Oppenheimer
MAINTAIN
MAINTAINOutperform
Mar 28, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$40.4K
sold · 6 insiders
DateInsiderTypeValue
Oct 5, 2026
Miller Mary
Chief Legal Officer
SELL$585.06
Aug 31, 2026
Levin Michaela
Chief Business Officer
AWARD130,000 sh
Aug 31, 2026
Levin Michaela
Chief Business Officer
AWARD30,000 sh
Aug 25, 2026
Blume-Jensen Peter
President and CEO
SELL$31.0K
Aug 18, 2026
Gamelin Erick
Chief Development Officer
SELL$804.00
Aug 18, 2026
Blume-Jensen Peter
President and CEO
SELL$972.84
Aug 18, 2026
Miller Mary
Chief Legal Officer
SELL$371.85
Aug 18, 2026
Peterson Katharine
Chief Accounting Officer
SELL$203.01

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only
Reddit mentions per day, 14 days
Crowd this week 56° Neutral 1 bullish · 0 bearish
Mentions, 7 days 4 1 in posts · 3 in comments
Recent posts
r/pennystocks Bullish 3d ago
$ACRV new drug reveal, adds another piece AP3 credibility, and the rapidly approaching readout could change everything.
1 upvotes · 1 comments
r/pennystocks Bullish 26d ago
Two new independent studies add even* more support to $ACRV
1 upvotes · 3 comments
Recent comments
r/pennystocks Neutral 2d ago
I set up an agent which checks for updates once an hour and sends me a push notification with any news updates from the official ACRV website, which is most likely going to be first source for news. Chances are it’ll be posted after hours.
r/pennystocks Neutral 3d ago
While I appreciate the hype having that many shares would make you a 3% share holder on the company. I highly doubt you own 3% of ACRV.
r/pennystocks Neutral 3d ago
What do you think of $ACRV upcoming major all comer readout slated around November.
All social signals and their track records

Short side

FINRA· Sep 30, 2026
1,616,727
shares short
+34.4%
vs prior settlement
4.4
days to cover
≈3.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 5, 2026 Insider
Miller Mary sold 294 shares
Chief Legal Officer @ $1.99 ($585.06)
Sep 30, 2026 Short interest report
Short Interest: ACRV up 34% to 1.6M shares
Settlement 2026-09-30 | Days to cover: 4.40 | ≈3.77% of shares outstanding (est.)
Aug 31, 2026 Insider
Levin Michaela was granted 130,000 shares
Chief Business Officer
Aug 31, 2026 Insider
Levin Michaela was granted 30,000 shares
Chief Business Officer
Jul 21, 2026 Press
Acrivon Therapeutics announced presentations at the AACR D3 conference highlighting preclinical and early clinical…
Impact 3/10
Jun 30, 2026 Inst.
RA CAPITAL MANAGEMENT, L.P. — ADD
12,229,396 shares ($21.8M)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
952,008 shares ($1.7M)
Jun 5, 2026 SEC
Acrivon Therapeutics filed a DEFA14A supplementing its definitive proxy for the June 17, 2026 Annual Meeting, adding a…
DEFA14A — Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Sep 30, 2026
Short interest
Short Interest: ACRV up 34% to 1.6M shares
Settlement 2026-09-30 | Days to cover: 4.40 | ≈3.77% of shares outstanding (est.)
Aug 31, 2026
Press release
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate…
Aug 19, 2026
Earnings date
ACRV Q2 2026 Earnings Scheduled — 2026-08-19
Aug 12, 2026
Earnings
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026
Aug 11, 2026
Earnings date
ACRV Q2 2026 Earnings Scheduled — 2026-08-11

SecBot reports

2 filings · 2 press releases · 0 bullish · 0 bearish · 2 neutral
All ACRV filing & press-release reports (4)